HIV/AIDS Elite Suppressors

	Tweet

HIV suppression maintained in HLA-B*57+ elite suppressors despite CTL escape mutations

Viral suppression is maintained in HIV-1-infected HLA-B*57+ elite suppressors despite cytotoxic T lymphocyte escape mutations.

According to a study from the United States, “Rare human immunodeficiency virus 1-infected individuals, termed elite suppressors (ES), maintain plasma virus levels of <50 copies/mL and normal CD4 counts without therapy.

"The major histocompatibility complex class I allele group human histocompatibility leukocyte antigen (HLA)-B*57 is over-represented in this population. Mutations in HLA-B*57 restricted epitopes have been observed in ES, but their significance has remained unclear.”

“Here we investigate the extent and impact of cytotoxic T lymphocyte (CTL) escape mutations in HLA-B*57+ ES. We provide the first direct evidence that most ES experience chronic low level viremia,” J.R. Bailey and colleagues at Johns Hopkins University reported.

“Sequencing revealed a striking discordance between the genotypes of plasma virus and archived provirus in resting CD4+ T cells. Mutations in HLAB* 57-restricted Gag epitopes were present in all viruses from plasma but were rare in proviruses, suggesting powerful selective pressure acting at these epitopes.

“Surprisingly,” said the authors, “strong CD8+ T cell interferon-gamma responses were detected against some mutant epitopes found in plasma virus, suggesting the development of de novo responses to viral variants. In some individuals, relative CD8+ T cell interleukin-2 responses showed better correlation with the selection observed in vivo.”

Scientists concluded, “Thus, analysis of low level viremia reveals an unexpectedly high level of CTL escape mutations reflecting selective pressure acting at HLA-B*57 restricted epitopes in ES. Continued viral suppression probably reflects CTL responses against unmutated epitopes and residual or de novo responses against epitopes with escape mutations.”

Bailey and colleagues published the results of their research in the Journal of Experimental Medicine (Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med, 2006;203(5):1357-1369).

For additional information, contact J.N. Blankson, Johns Hopkins University, School Medical, Dept. of Medical, Baltimore, MD 21287, USA.

The publisher of the Journal of Experimental Medicine can be contacted at: Rockefeller University Press, 1114 First Avenue, 4TH FL, New York, NY 10021, USA.

RELATED STORIES:
FDA Advisory Panel Approves Home HIV Test Kit   FDA Approves New In-Home HIV Test   Home HIV test advances   Survey Reveals Support for Over-the Counter HIV Testing   F.D.A. Panel Weighs Preventive Use of H.I.V. Drug   Stem Cell Therapy Shows Promise in Fight Against HIV   Progress against HIV thwarted by patients’ unmet needs   California to test pill for HIV prevention   Mechanism of HIV spread has potential for future drug therapy   Seeking HIV treatment clues in the neem tree   HIV Prevention Pill’s Value Varies by Target   Using AIDS drugs to prevent infection: a bargain?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]